Semaglutide Online — Real Results, No Waiting Room

Yes — semaglutide is the active ingredient in both Wegovy® and Ozempic®. The key difference is the approved indication and dose. Ozempic® (semaglutide up to 2.0mg) is FDA-approved for type 2 diabetes management. Wegovy® (semaglutide 2.4mg) is FDA-approved specifically for chronic weight management in adults with obesity or overweight with a weight-related condition. Compounded semaglutide contains the same active molecule and is prepared by licensed 503B outsourcing pharmacies. All three work through the same GLP-1 receptor mechanism to reduce appetite and promote weight loss. Truventa prescribes both compounded and brand-name options depending on your clinical profile and preferences.

In the landmark STEP 1 trial — the largest randomized trial of semaglutide for weight loss — participants taking semaglutide 2.4mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo. For someone weighing 200 pounds, that's roughly 30 pounds. Over 1 in 3 participants lost more than 20% of their body weight. In the 2-year STEP 5 trial, patients maintained an average weight loss of 15.2%. Real-world results vary depending on starting weight, adherence, diet, and lifestyle. Most patients begin to notice reduced appetite and early weight loss within the first 4–8 weeks.

Compounded semaglutide from a licensed 503B outsourcing facility uses the same semaglutide active pharmaceutical ingredient as brand-name products. 503B facilities are registered with the FDA and operate under current Good Manufacturing Practice (cGMP) standards — subject to regular inspections. While compounded medications are not individually FDA-approved as finished products, the underlying molecule, pharmacology, and safety profile of semaglutide are extensively documented through years of clinical research and post-market surveillance. At Truventa Medical, we work exclusively with verified, licensed 503B compounding pharmacies. Your prescribing physician will thoroughly review your health history to ensure semaglutide — in any form — is appropriate and safe for you.

Semaglutide is administered as a subcutaneous (under-the-skin) injection, given once per week on the same day each week. For brand-name Wegovy®, it comes in a pre-filled single-use auto-injector pen — similar in use to an EpiPen. Compounded semaglutide typically comes in a multi-dose vial with syringes and needles. Injections are self-administered in the abdomen, outer thigh, or upper arm. The needle is very fine (4–6mm, 32 gauge) and most patients describe minimal discomfort — comparable to a small pinch. Your Truventa care team provides step-by-step injection training materials and support. After the first injection, most patients feel confident injecting on their own.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and stomach discomfort. These are most prominent during the initial dose escalation phase and tend to improve significantly as your body adjusts. Strategies like eating smaller meals, avoiding high-fat foods, staying hydrated, and slowing down dose escalation can help minimize GI symptoms.

Semaglutide carries an important boxed warning: in rodent studies at high doses, it caused thyroid C-cell tumors. It should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Less common but serious risks include pancreatitis, gallbladder disease, and hypoglycemia (particularly in patients also taking insulin or sulfonylureas). Your Truventa physician will carefully review your medical history before prescribing to ensure it is safe for you.

Semaglutide is indicated for long-term, chronic weight management — not as a short-term fix. Clinical evidence from the STEP trials shows that most weight loss occurs in the first 6–12 months, but the medication continues to provide benefit with ongoing use. Critically, the STEP 4 trial demonstrated that patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of their lost weight within one year — highlighting obesity as a chronic, relapsing condition that often requires sustained treatment.

Your Truventa physician will work with you to develop a long-term treatment plan tailored to your goals. Options may include continued therapy, a structured tapering protocol, or transitioning to a weight maintenance phase once goal weight is achieved. We are committed to transparent, evidence-based counseling so you can make informed decisions about your health.